Ma Kai, Wang Tian-you, He Bao-liang, Chang Dong, Hu Xiao-dan, Yin Zhi-yi, Jiang Hua, Cui Yong, Gao Zhi, Gong Min
Department of Thoracic and Cardiovascular Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Zhonghua Wai Ke Za Zhi. 2009 Jan 15;47(2):120-2.
To study the survival and prognostic implication in surgically resected satellite-nodule T4 (T4 satellite) non-small cell lung cancer (NSCLC).
From January 1995 to March 2005, the complete resection was performed to 42 patients with NSCLC who were postoperatively identified as pathologic-stage T4 satellite. Survival and associations between clinicopathological parameters and prognosis were analyzed. Thirty-two patients with pathologic stage local-invasion T4 (T4 invasion) NSCLC who underwent resection at the same time were also analyzed.
The 1-, 3- and 5-year survival was 76.2%, 57.1% and 46.0% for patients with T4 satellite, while 62.3%, 31.5% and 20.0% for patients with T4 invasion. There was a significant higher survival in T4 satellite group when compared to that in T4 invasion group (P < 0.05). Furthermore, patients with T4 satellite N0M0 got a better survival than those with T4 satellite N1-2M0, T4 invasion N0M0 and T4 invasion N1 -2M0 (P < 0.05). For patients with T4 satellite, univariate analysis showed that histology, main tumor size, lymph node status and adjuvant chemotherapy were linked with survival, while main tumor size, lymph node status and adjuvant chemotherapy served as the independent prognostic factors with multivariate analysis.
Patients with completely resected T4 satellite NSCLC have a better prognosis than those with T4 invasion. Main tumor size over 3 cm, lymph node metastasis or no adjuvant chemotherapy means an unfavorable prognosis.
研究手术切除的卫星结节T4(T4卫星)非小细胞肺癌(NSCLC)的生存情况及预后意义。
1995年1月至2005年3月,对42例术后病理分期为T4卫星的NSCLC患者进行了根治性切除。分析了生存情况以及临床病理参数与预后之间的关联。同时还分析了32例同期接受手术切除的病理分期为局部浸润T4(T4浸润)NSCLC患者。
T4卫星患者的1年、3年和5年生存率分别为76.2%、57.1%和46.0%,而T4浸润患者分别为62.3%、31.5%和20.0%。与T4浸润组相比,T4卫星组的生存率显著更高(P<0.05)。此外,T4卫星N0M0患者的生存率优于T4卫星N1-2M0、T4浸润N0M0和T4浸润N1-2M0患者(P<0.05)。对于T4卫星患者,单因素分析显示组织学、主肿瘤大小、淋巴结状态和辅助化疗与生存相关,而多因素分析显示主肿瘤大小、淋巴结状态和辅助化疗是独立的预后因素。
完全切除的T4卫星NSCLC患者的预后优于T4浸润患者。主肿瘤大小超过3 cm、淋巴结转移或未接受辅助化疗意味着预后不良。